TG Therapeutics Inc
TGTX29.990USD
-5.030-14.36%
Market hours （ET）Quotes delayed by 15 min
4.74BMarket Cap
121.16P/E TTM
More Details of TG Therapeutics Inc Company
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Company Info
Ticker SymbolTGTX
Company nameTG Therapeutics Inc
IPO dateDec 14, 1995
CEOMr. Michael S. Weiss, J.D.
Number of employees338
Security typeOrdinary Share
Fiscal year-endDec 14
Address3020 Carrington Mill Blvd., Suite 475
CityMORRISVILLE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code27560-5435
Phone18775758489
Websitehttps://www.tgtherapeutics.com/
Ticker SymbolTGTX
IPO dateDec 14, 1995
CEOMr. Michael S. Weiss, J.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
13.82M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
600.61K
-19.72%
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
+5.56%
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
228.82K
+2.11%
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
222.89K
+10.63%
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
+8.27%
Dr. Sagar Lonial
Dr. Sagar Lonial
Independent Director
Independent Director
114.91K
+14.69%
Name
Name/Position
Position
Shareholding
Change
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
13.82M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
600.61K
-19.72%
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
+5.56%
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
228.82K
+2.11%
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
222.89K
+10.63%
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
+8.27%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
By BusinessUSD
Name
Revenue
Proportion
Total product revenue, net
119.66M
99.01%
Royalty Revenue
605.00K
0.50%
Other Revenue
558.00K
0.46%
License Revenue
38.00K
0.03%
Milestone Revenue
0.00
0.00%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Total product revenue, net
119.66M
99.01%
Royalty Revenue
605.00K
0.50%
Other Revenue
558.00K
0.46%
License Revenue
38.00K
0.03%
Milestone Revenue
0.00
0.00%
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.11%
The Vanguard Group, Inc.
9.81%
Weiss (Michael S)
8.71%
State Street Global Advisors (US)
4.68%
Geode Capital Management, L.L.C.
2.07%
Other
62.63%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.11%
The Vanguard Group, Inc.
9.81%
Weiss (Michael S)
8.71%
State Street Global Advisors (US)
4.68%
Geode Capital Management, L.L.C.
2.07%
Other
62.63%
Shareholder Types
Shareholders
Proportion
Investment Advisor
35.59%
Investment Advisor/Hedge Fund
16.95%
Individual Investor
9.74%
Hedge Fund
4.94%
Research Firm
3.73%
Pension Fund
1.23%
Bank and Trust
0.41%
Sovereign Wealth Fund
0.25%
Family Office
0.13%
Other
27.03%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
691
115.81M
72.94%
-20.80M
2025Q1
704
116.82M
73.80%
-25.76M
2024Q4
657
113.87M
72.65%
-36.14M
2024Q3
598
117.83M
76.11%
-20.28M
2024Q2
544
109.58M
70.90%
-28.91M
2024Q1
535
105.41M
68.45%
-29.01M
2023Q4
542
104.64M
69.13%
-36.73M
2023Q3
552
104.67M
69.33%
-30.54M
2023Q2
543
102.45M
68.58%
-35.33M
2023Q1
550
108.72M
74.29%
-22.90M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
19.22M
12.11%
-465.28K
-2.36%
Mar 31, 2025
The Vanguard Group, Inc.
15.57M
9.81%
+8.03K
+0.05%
Mar 31, 2025
Weiss (Michael S)
13.82M
8.71%
--
--
Apr 14, 2025
State Street Global Advisors (US)
7.43M
4.68%
-1.77M
-19.20%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.28M
2.07%
+89.06K
+2.79%
Mar 31, 2025
Soleus Capital Management, L.P.
2.85M
1.79%
+165.46K
+6.17%
Mar 31, 2025
ClearBridge Investments, LLC
2.64M
1.67%
+809.33K
+44.10%
Mar 31, 2025
Pictet Asset Management Ltd.
2.40M
1.51%
-396.75K
-14.20%
Mar 31, 2025
Fidelity Management & Research Company LLC
1.74M
1.1%
+710.43K
+68.88%
Mar 31, 2025
Hood River Capital Management LLC
1.56M
0.98%
+101.17K
+6.95%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco S&P SmallCap Health Care ETF
3.49%
Invesco Biotechnology & Genome ETF
2.71%
Virtus LifeSci Biotech Products ETF
1.86%
SPDR S&P Biotech ETF
1.72%
Invesco S&P SmallCap 600 Pure Growth ETF
1.69%
Direxion Daily S&P Biotech Bull 3X Shares
0.98%
Invesco S&P SmallCap Momentum ETF
0.95%
SPDR S&P 600 Small Cap Growth ETF
0.71%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.71%
First Trust NASDAQ Pharmaceuticals ETF
0.67%
View more
Invesco S&P SmallCap Health Care ETF
Proportion3.49%
Invesco Biotechnology & Genome ETF
Proportion2.71%
Virtus LifeSci Biotech Products ETF
Proportion1.86%
SPDR S&P Biotech ETF
Proportion1.72%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.69%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.98%
Invesco S&P SmallCap Momentum ETF
Proportion0.95%
SPDR S&P 600 Small Cap Growth ETF
Proportion0.71%
Vanguard S&P Small-Cap 600 Growth Index Fund
Proportion0.71%
First Trust NASDAQ Pharmaceuticals ETF
Proportion0.67%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
